ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 136 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 4.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $80 | -43.3% | 15,041 | +1.6% | 0.00% | – |
| Q2 2023 | $141 | -46.6% | 14,802 | -38.2% | 0.00% | – |
| Q1 2023 | $264 | -40.4% | 23,966 | -20.0% | 0.00% | -100.0% |
| Q4 2022 | $443 | -99.9% | 29,951 | +21.8% | 0.00% | 0.0% |
| Q3 2022 | $470,000 | -9.6% | 24,584 | +0.8% | 0.00% | 0.0% |
| Q2 2022 | $520,000 | +42.5% | 24,387 | +28.7% | 0.00% | – |
| Q1 2022 | $365,000 | -7.1% | 18,953 | +0.1% | 0.00% | – |
| Q4 2021 | $393,000 | -13.4% | 18,933 | -0.3% | 0.00% | – |
| Q3 2021 | $454,000 | -30.4% | 18,995 | -20.5% | 0.00% | -100.0% |
| Q2 2021 | $652,000 | +23.7% | 23,892 | +31.3% | 0.00% | 0.0% |
| Q1 2021 | $527,000 | +2.9% | 18,200 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $512,000 | +86.2% | 18,200 | +93.6% | 0.00% | – |
| Q3 2020 | $275,000 | -3.2% | 9,400 | 0.0% | 0.00% | – |
| Q2 2020 | $284,000 | – | 9,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |